Determination of phosphodiesterase 5 (PDE5)inhibitors in instant coffee premixes using liquid chromatography-high-resolution mass spectrometry (LC-HRMS) by Mohd Yusop, AY et al.
Elsevier required licence: © <2019>. This manuscript version is made available under the CC-BY-NC-ND 4.0 
license http://creativecommons.org/licenses/by-nc-nd/4.0/        
The definitive publisher version is available online at https://doi.org/10.1016/j.talanta.2019.05.078
1 
 
Determination of phosphodiesterase 5 (PDE5) inhibitors in instant coffee 
premixes using liquid chromatography-high-resolution mass spectrometry (LC-
HRMS) 
 
Ahmad Yusri Mohd Yusopa,b, Linda Xiaoa, Shanlin Fua* 
aCentre for Forensic Science, University of Technology Sydney, Ultimo, NSW, 2007 
Australia 




E-mail address: shanlin.fu@uts.edu.au 
 
Abstract 
As a widely consumed beverage, coffee tends to be a target for intentional 
adulteration. This study describes the application of modified quick, easy, cheap, 
effective, rugged, and safe (QuEChERS) coupled to liquid chromatography-high-
resolution mass spectrometry (LC-HRMS) for simultaneous screening, identification, 
and quantification of undeclared phosphodiesterase 5 (PDE5) inhibitors in instant 
coffee premixes (ICPs). The mass spectrometer was operated in auto MS/MS 
acquisition for simultaneous MS and MS/MS experiments. Qualitative establishments 
from the suspected-target screening and targeted identification processes led to an 
unambiguous analyte assignment from the protonated molecule ([M+H]+) precursor 
ion which is subsequently used for quantification of 23 targeted PDE5 inhibitors. The 
analytical method validation covered specificity, linearity, range, accuracy, limit of 
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detection (LOD), limit of quantification (LOQ), precisions, matrix effect (ME), and 
extraction recovery (RE). The specificity was established using the optimised 
chromatographic separation as well as the distinguishable [M+H]+ precursor ion. The 
linearity of each target analyte was demonstrated with a coefficient of determination 
(r2) of >0.9960 over the expected range of sample concentrations. The accuracy 
ranged from 88.1%–119.3% with LOD and LOQ of <70 ng/mL and 80 ng/mL, 
respectively. Excellent precisions were established within 0.4%–9.1% of the relative 
standard deviation. An insignificant ME within –5.2% to +8.7% was achieved using 
three different strategies of chromatography, sample extraction, and sample dilution. 
The RE was good for all target analytes within 84.7%–123.5% except for N-
desethylacetildenafil at low (53.8%) and medium (65.1%) quality control levels. The 
method was successfully applied to 25 samples of ICPs where 17 of them were found 
to be adulterated with PDE5 inhibitors and their analogues. Further quantification 
revealed the total amount of these adulterants ranged from 2.77 to 121.64 mg per 
sachet. 
 




Coffee is among the most favoured beverages throughout the world [1], leading to the 
advent of instant coffee premixes (ICPs) which typically packaged in a single serving 
sachet. These coffee products often comprise other ingredients such as creamer, 
sugar and ingredients to enrich flavour and texture [2, 3]. Sometimes, they are fortified 
with vitamins and minerals [4]. Unfortunately, ICPs are also known to be adulterated 
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with synthetic drugs which claim to enhance male sexual performance such as 
phosphodiesterase 5 (PDE5) inhibitors and their analogues. 
 
An analogue of PDE5 inhibitors is synthesised by minor modifications to the parent 
structure of the approved drugs which will alter their physical and chemical properties 
[5]. Additionally, there are no clinical studies performed on these analogues to ensure 
their efficacy and safety [6]. To date, more than 90 unapproved analogues of PDE5 
inhibitors have been discovered and described in the literature as adulterants. Since 
2010 up to the end of 2018, the United States Food and Drug Administration has 
issued seven warnings regarding ICPs tainted with PDE5 inhibitors and their 
analogues [7], specifically those that were made in Malaysia [8].  
 
Liquid chromatography (LC) coupled with mass spectrometry (MS) has been most 
popular in the detection and analysis of PDE5 inhibitors and their analogues. Although 
low-resolution MS was frequently used [9–11], high-resolution mass spectrometry 
(HRMS) proves to be superior [12–14] as it delivers full spectral information with 
excellent mass accuracy on top of isotopic reliability, aiding suspected-target 
screening [15] and targeted identification processes [16]. It also enables embedding 
non-targeted screening into a developed method for retrospective and prospective 
applications [17]. To date, analysis of PDE5 inhibitors has been primarily targeting 
health supplements, particularly in pharmaceutical dosage form [18]. Due to the 
relatively high concentration of analytes in these products and the relatively simple 
matrix involved, these published methods are not applicable in the analysis of PDE5 
inhibitors in ICPs. The low analyte level and the complex matrix nature of ICPs in 
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combination with the growing number of novel PDE5 analogues available for 
adulteration represent a real analytical challenge for forensic drug testing laboratories.  
 
This study focused on developing an LC-HRMS based analytical method that is 
capable of accurately detecting and quantifying PDE5 inhibitors and their analogues 
down to trace levels in ICPs. Method development involved optimisation of 
chromatographic separation, MS conditions, and sample preparation, described in 
[19]. Method validation covered specificity, linearity, range, accuracy, limit of detection 
(LOD), limit of quantification (LOQ), precisions, matrix effect (ME), and extraction 
recovery (RE). The method was applied to real sample analysis incorporating 
suspected-target screening, targeted identification, quantification, and non-targeted 
screening approaches. To the best of our knowledge, this is the first report to 
comprehensively address the analytical challenge for a reliable determination of PDE5 
inhibitors as adulterants in ICPs. 
 
2. Materials and methods 
2.1. Chemicals and reagents 
Certified reference materials were purchased from TLC Pharmaceutical Standards 
Ltd. (Aurora, Ontario, Canada). They are desmethylcarbodenafil (1), carbodenafil (2), 
N-desethylacetildenafil (3), acetildenafil (4), hydroxyvardenafil (5), 
dimethylacetildenafil (6), vardenafil (7), sildenafil (8), homosildenafil (9), 
dimethylsildenafil (10), propoxyphenyl-hydroxyhomosildenafil (11), udenafil (12), 
propoxyphenyl-sildenafil (13), hydroxythiovardenafil (14), tadalafil (15), mirodenafil 
(16), mutaprodenafil (17), thiosildenafil (18), thiohomosildenafil (19), 
dithiodesmethylcarbodenafil (20), thiodimethylsildenafil (21), propoxyphenyl-
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thiohydroxyhomosildenafil (22), and propoxyphenyl-thiodimethylsildenafil (23). Their 
chemical structures are presented in Fig. S1. LC-MS grade methanol and acetonitrile 
were purchased from Chem-Supply Pty Ltd. (Gillman, SA, Australia). LC-MS grade 
formic acid and analytical grade ammonium formate were purchased from Sigma 
Aldrich Pty Ltd. (Castle Hill, NSW, Australia). Ultrapure water (18.2 MΩ-cm) was 
obtained from a Sartorius arium® pro ultrapure water system (Goettingen, Germany). 
Restek Q-sep QuEChERS extraction salts (EN 15662) was purchased from LECO 
Australia Pty Ltd. (Castle Hill, NSW, Australia). 
 
2.2. Standard solution preparation 
All 23 individual stock solutions of PDE5 inhibitors were prepared separately in LC-
MS grade methanol at 1 mg/mL and stored in the dark at 4°C until analysis. A mixture 
of all standards (working solution) was prepared fresh for each analysis from the stock 
solutions by further dilution in methanol to make up to 25 µg/mL concentration. 
 
2.3. Sample collection and storage 
A total of 25 distinct brands of ICPs were acquired from Malaysia. These samples are 
highly suspected to be adulterated with PDE5 inhibitors based on the references to 
male sexual performance in their brand names, label claims, images, botanical 
ingredients, or advertising materials. Out of the total, 13 samples were kindly donated 
by the Pharmacy Enforcement Division, Ministry of Health Malaysia, obtained from 
surveillance activities (7 samples), and by confiscation at the international airport (2 
samples) and international seaport (4 samples) during routine inspections by 
pharmacy enforcement officers. The other 12 samples were purchased through online 
shopping platforms in Malaysia. All distinct samples were coded and labelled as 
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SPL001 to SPL025. These samples were deposited in a plastic zip lock bag separately 
and then stored in an airtight container in the dark. A blank ICP, free from any analyte 
of interests was sourced from a local supermarket and used for method development 
and validation. 
 
2.4. Sample preparation 
First, the whole content of a sachet of an ICP sample was weighed. Then, 100 mg of 
the sample was dissolved in 5 mL of acetonitrile and methanol (50:50, v/v). The 
resulting solution was then transferred into a tube prefilled with QuEChERS salts for 
the extraction procedure. Finally, the upper layer was filtered and diluted with methanol 
at 1:10 dilution level for analysis. The blank ICP was treated in the same manner as 
the steps described for the sample analysis. The full extraction procedures can be 
found in Section 2.1 of Ref. [19]. 
 
2.5. LC-HRMS conditions 
The chromatographic separation was performed using an Agilent Technologies (Santa 
Clara, CA, USA) 1290 Infinity II LC system coupled to an Agilent Technologies 6510 
quadrupole time of flight-mass spectrometer (QTOF-MS). The LC system was fitted 
with a reverse phase high-performance LC column from Merck KGaA (Darmstadt, 
Germany) Chromolith® High-Resolution RP-18 end-capped (100 x 4.6 mm, 2.0 µm) 
with solvent A (10 mM ammonium formate in ultrapure water) and solvent B 
(acetonitrile). Both solvents were acidified with 0.1% v/v formic acid as the binary 
mobile phase system. The QTOF-MS was operated in positive electrospray ionisation 
mode with auto MS/MS acquisition. Specific details on the LC-HRMS conditions are 
described in Section 2.2 of Ref. [19]. 
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2.6. Method validation and data analysis 
Method validation was performed in accordance with the guideline set by the 
International Conference on Harmonisation [20] covering specificity, linearity, range, 
accuracy, LOD, LOQ, and precisions. The ME and RE were also evaluated for each 
target analyte in the blank ICP matrix following the published procedures [21]. All 
analyses were done in triplicate. 
 
The specificity was assessed for each target analyte based on their chromatographic 
resolution and their unique accurate mass of the protonated molecule ([M+H]+) 
precursor ion from the MS experiment. The presence of two fragment ions 
corresponding to each targeted PDE5 inhibitors was established from the MS/MS 
experiment. To further confirm the identity of each target analyte, the average intensity 
ratio between the first and the second fragment ion was compared to those obtained 
from the linearity assessment with an acceptable value of ±30%. The effects of 
interferences, especially from the blank ICP matrix, were ascertained by the evaluation 
of three levels of quality control (QC) analytes and analyte-free extracted blank matrix. 
 
Six-point external calibration curves were constructed for each target analyte by 
diluting the working solution in methanol at concentrations ranged from 0.08 to 1.2 
µg/mL. The individual analyte peak areas, from the [M+H]+ precursor ion versus 
analyte concentrations, were utilised to construct an external calibration curve. A 
regression analysis was done to determine the linearity based on the coefficient of 
determination (r2) and the regression equation was used to calculate the QC analytes 
and samples concentrations. The linear range was established based on the lower 
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(trace level) and upper (lowest recommended dose) concentrations of analyte 
expected in adulterated ICPs. 
 
The accuracy was established at low, medium, and high QC levels. All target analytes 
were spiked into an extracted blank ICP, and the resulting peak area of the [M+H]+ 
precursor ion was fitted to the regression equation of the external calibration curve to 
determine its concentration. Comparison of the observed analyte concentration versus 
the expected concentration at the same QC level was expressed as a percentage of 
accuracy with an acceptable value of ±25%. 
 
The LOD and LOQ were determined experimentally based on the visual evaluation 
approach. For LOD, solutions were prepared with an initial 100 ng/ml concentration of 
target analytes. The solutions were then decreased by 10 ng/ml each down to the final 
solution of 10 ng/ml. The LOD was set at the lowest concentration of target analyte 
that can be reliably detected based on the presence and the average intensity ratio of 
two fragment ions described in the specificity assessment. Meanwhile, the LOQ was 
defined as the lowest concentration of the calibration curve, where each target analyte 
can be quantified with an acceptable percentage of accuracy of ±25% and precision 
based on the percentage of relative standard deviation (%RSD) of less than 20%. 
 
Using the same QC analytes in an extracted blank matrix, precisions were determined 
based on repeatability and intermediate precision at low, medium, and high QC levels. 
Repeatability and intermediate precision were established at intra- and inter-day, 
respectively, and expressed as a %RSD of the peak areas of the [M+H]+ precursor ion 
with an acceptable value of less than 20%. 
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The ME was evaluated based on the post-extraction addition method by comparing 
the slopes of the matrix-matched calibration curve versus those of the external 
calibration curve in a neat solution as expressed by Eq. 1. Both calibration curves were 
constructed using the same concentration as the QC analytes. The percentage of ME 
was then categorised in accordance with the set criteria of insignificant (0% to ±10%), 
acceptable (±10% to ±20%), moderate (±20% to ±50%), and severe (–50%<>+50%), 
where positive value indicates ionisation enhancement while negative value indicates 
ionisation suppression. 
 
𝑀𝐸 (%) = [
𝑆 𝑚𝑎𝑡𝑟𝑖𝑥 𝑚𝑎𝑡𝑐ℎ𝑒𝑑
𝑆 𝑛𝑒𝑎𝑡 𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛
− 1] × 100 (Eq. 1) 
where  
S  = the slope of the calibration curve 
 
The RE was determined by comparing the peak areas of the [M+H]+ precursor ion of 
target analytes spiked into the blank ICP matrix before extraction versus those spiked 
into an extracted blank matrix at the same concentration. The RE was expressed in 
percentage at low, medium, and high QC levels with an acceptable value of ±25%.  
 
All qualitative and quantitative data were processed using Agilent Technologies Mass 
Hunter workstation software version B.07.00 and personal compound database and 
library (PCDL) manager software version B.04.00. All other calculations were done 






2.7. Workflow for determination of PDE5 inhibitors in ICPs 
The targeted analysis workflow employed (1) the suspected-target screening, (2) the 
targeted identification, and (3) the quantification of identified PDE5 inhibitors. The non-
targeted screening workflow covered both top-down and bottom-up approaches to 
identify novel PDE5 inhibitors. Fig. 1 summarises the LC-HRMS workflow for the 
targeted analysis and the non-targeted screening employed in this study. 
 
The initial suspected-target screening workflow was based on a matching algorithm 
when an observed accurate mass of the [M+H]+ precursor ion was compared to those 
theoretical ones in the database for a possible match and thus possible presence of a 
PDE5 inhibitor. Moreover, the isotope distribution pattern was also compared for a 
match based on its abundance and spacing. For this purpose, a personal MS 
compound database was created using the PCDL software based on the currently 
known PDE5 inhibitors found as adulterants in literature. The database contained a 
total of 95 PDE5 inhibitors with a comprehensive collection of the compound name, 
molecular formula and structure, and exact mass. The mass accuracy for the MS 
matching was set at 5 ppm windows with isotope abundance distribution and spacing 
score of more than 80%. A positive match of the suspected PDE5 inhibitors will be 
subjected to the targeted identification workflow while a negative match will be further 
investigated using the non-targeted screening workflow. 
 
The targeted identification workflow relied on the matching of the observed retention 
time and two observed fragment ions with those of target analytes stored in the same 
database which included only the 23 PDE5 inhibitors. The same database comprises 
additional information on the retention time and MS/MS spectral library of target 
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analytes at different collision energies (CEs). The mass accuracy for the MS/MS 
matching was set at 20 ppm windows with a retention time difference of up to ±0.25 
minutes. 
 
The quantification workflow was only applied to samples positive in the targeted 
identification process. The final dose of the adulterants in each ICP sachet was 
calculated based on Eq. 2. 
 
𝐹𝑖𝑛𝑎𝑙 𝑑𝑜𝑠𝑒 =
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑜𝑛𝑐. 𝑓𝑟𝑜𝑚 𝑟𝑒𝑔𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑒𝑞.
(𝐴𝑛𝑎𝑙𝑦𝑠𝑖𝑠 𝑐𝑜𝑛𝑐.× 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙) 
× 𝑊𝑒𝑖𝑔ℎ𝑡 𝑝𝑒𝑟 𝑠𝑎𝑐ℎ𝑒𝑡 (Eq. 2) 
where 
Average conc. from regression eq. = concentration of target analyte calculated from the 
regression equation of the external calibration curve (n=3) 
Analysis conc. = concentration of an ICP used in sample preparation 
Dilution level  = level of dilution from the initial analysis concentration 
Weight per sachet  = total weight of ICP per sachet 
 
The quantification levels were divided into subtherapeutic, therapeutic, and 
supratherapeutic based on the dose recommended by the approved PDE5 inhibitors. 
For the comparative purpose of this study, the quantification levels of unapproved 
PDE5 inhibitors analogues were linked to the therapeutic dosage of their 
corresponding approved drugs, i.e. 25 to 100 mg for sildenafil and 5 to 20 mg for 
vardenafil and tadalafil. The determination of trace concentrations was based on a 




The non-targeted screening workflow was employed for further investigation of 
negative samples from the suspected-target screening. The non-targeted screening 
approach used in this study was adapted and modified according to the critical review 
by Pasin et al. [17]. Based on the visual inspection of the chromatographic peak, the 
top-down and bottom-up approaches were both employed to detect any novel PDE5 
inhibitors. A top-down approach was utilised for visible chromatographic peaks. All 
visible peaks within the base peak chromatogram (BPC) were integrated and extracted 
to reveal the mass spectra. Each mass spectrum was interrogated with the highest 
abundance peak selected as a possible [M+H]+ precursor ion of novel PDE5 inhibitors. 
The relationship between the selected [M+H]+ precursor ion was established with the 
fragment ions of target analytes via product ion scan at MS/MS level of the Mass 
Hunter workstation software to reveal any common fragmentation pattern. Conversely, 
a bottom-up approach was utilised for non-visible chromatographic peaks where the 
extracted ion chromatograms (EICs) were generated based on the fragment ions of 
target analytes at different CEs. Using this approach, no prior knowledge of the [M+H]+ 
precursor ion is available. Therefore, all possible [M+H]+ precursor ions generated 
from the MS experiment were considered as novel PDE5 inhibitors. The presence of 
class-specific EICs of the product ion scan at MS/MS level may reveal the presence 
of novel PDE5 inhibitors which can be further interrogated and linked with their distinct 
[M+H]+ precursor ion. Both of these approaches aimed to reveal any common 
fragmentation pattern that could be linked to any known PDE5 inhibitors and thus, 






3. Results and Discussion 
3.1. Analytical method optimisation and validation 
The analytical method optimisation as a whole addressed the issue of MEs from 
complex matrices such as ICPs. Also, the presence of four different groups of 
structural isomers was tackled chromatographically, leading to a baseline 
chromatographic separation, enhancing the specificity of each isomeric analyte. Other 
chromatographic optimisation discussed in Section 2.3 of Ref. [19] resulted in 
improved peak shape and resolution, and reproducible retention time for each target 
analyte. The presence of sodium adducts was addressed during the MS optimisation 
and thus improved the selectivity and sensitivity of the MS and MS/MS experiments. 
The modified QuEChERS extraction procedure was successfully developed following 
poor MEs using the conventional dilute and shoot technique during the sample 
preparation optimisation. In conclusion, the success of the analytical method 
optimisations discussed in this study is significant for a definitive screening, 
identification, and quantification of PDE5 inhibitors and their analogues from ICPs. 
 
The specificity was successfully demonstrated using the developed chromatographic 
separation as presented in Fig. 2. Target analytes in extracted blank ICP at all QC 
levels could be correctly identified using the distinguishable [M+H]+ precursor ion 
without any interference from the matrix components. Conversely, the analyte-free 
extracted blank matrix returned insignificant signals corresponding to all target 
analytes at their retention times. The presence of two fragment ions correspondingly 
ensured the specificity of the method and the average intensity ratio confirmed the 




The linearity of the method was confirmed for each target analyte with a coefficient of 
determination (r2) larger than 0.9960. The selected range proved to suffice for 
quantification of target analytes ranging from trace level up to supratherapeutic 
concentrations from the ICP matrix. The percentage of accuracy ranged from 88.1%–
119.3% at low; 94.8%–110.3% at medium; and 100.6%–109.3% at high QC level. The 
LOD and LOQ for all target analytes ranged from 10–70 ng/mL and 80 ng/mL, 
respectively. These results are presented in Table 3 of Ref. [19]. 
 
Table 4 of Ref. [19] shows the results of precisions, ME and RE. The method produced 
good repeatability at low, medium, and high QC levels with the %RSD ranging from 
0.4%–7.3%; 1.0%–6.2%; and 0.6%–3.1%, respectively. In agreement with the 
repeatability results, the intermediate precision was calculated to be within 0.6%–7.2% 
at low; 0.6%–7.7% at medium; and 0.5%–9.1% at high QC level. Insignificant MEs 
were observed for all target analytes within –5.2% to +8.7% whereas the RE proved 
to be satisfactory at all QC levels within 84.7%–123.5% except for N-
desethylacetildenafil at low (53.8%) and medium (65.1%) QC levels.  
 
3.2. Analysis of PDE5 inhibitors in ICPs 
A total of 25 ICP samples were submitted to the LC-HRMS analysis for the 
determination of PDE5 inhibitors. The initial suspected-target screening resulted in 17 
positive samples, of which 15 were further confirmed using the targeted identification 
process and quantified. The non-targeted screening workflow detected no suspicious 
compounds, so there were no analytes of novel PDE5 inhibitors flagged from the ICP 
samples. In summary, 9 samples were adulterated with one PDE5 inhibitor, 2 samples 
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with two inhibitors, and the rest 6 samples with three and four inhibitors for each 3 
samples, respectively, as shown in Fig. S2 (A). 
 
Collectively, eight distinct PDE5 inhibitors were determined using the targeted 
identification workflow while another two highly suspected adulterants were detected 
through the suspected-target screening workflow. The most prominent adulterant was 
sildenafil which was identified in 4 samples as a single adulterant and 5 samples in 
combinations with other PDE5 inhibitors. Other adulterants of PDE5 inhibitors 
discovered in this study included dimethylsildenadil, thiodimethylsildenafil, and 
thiosildenafil (5 samples each), tadalafil (3 samples), desmethylcarbodenafil (2 
samples), and propoxyphenyl-thiodimethylsildenafil and propoxyphenyl-sildenafil (1 
sample each) either in combination with each other or as a single adulterant. 
 
Only 15 samples were quantified with these adulterants found at subtherapeutic levels 
up to supratherapeutic concentrations ranged from 2.77 to 121.64 mg per sachet of 
the ICP sample. Although distinct PDE5 inhibitors may be quantified at trace, 
subtherapeutic, and therapeutic levels, a combination of these adulterants in one 
sachet of ICP may subsequently result in supratherapeutic concentrations as 
presented in SPL004, SPL015, SPL019, SPL020, and SPL024. The sample dilution 
approach employed in this study proved to be excellent for the determination of PDE5 
inhibitors at trace and subtherapeutic levels. For quantification of adulterants at 
therapeutic and supratherapeutic concentrations, the dilution level of up to 1:100 was 
deemed to be sufficient. However, the fact that multiple adulterants may be present in 
a sample and often at different concentration levels, required at least another further 
sample dilution for accurate and precise quantification of each target analyte. A 
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detailed content of each sachet of ICP samples is presented in Table 1 and Fig. S2 
(C) summarises the results. 
 
Qualitative establishments from the suspected-target screening and targeted 
identification processes had revealed two highly suspected PDE5 inhibitors in three 
different samples. SPL002 and SPL006 exhibited a prominent peak at 23.63 and 23.65 
minutes, respectively, for each of their BPC. Each of these samples was initially 
matched with two possible structural isomers, i.e. hydroxythiohomosildenafil and 
hydroxythiovardenafil based on its [M+H]+ precursor ion at m/z 521.1999, with mass 
errors of 0.00 ppm for SPL002 and 0.19 ppm for SPL006. Moreover, the isotope 
abundance distribution and spacing score of more than 90% correspondingly 
approved the matched compounds. The suspected compound has a similar 
fragmentation pattern with thiohomosildenafil at three different CEs and hence, 
construed its identity as a possible analogue of thiohomosildenafil. Due to the 
additional 16 Da mass unit of hydroxythiohomosildenafil, which corresponds to an 
oxygen atom, their fragmentation patterns are expected to be the same [23]. 
 
In contrast, the BPC of SPL005 revealed a prominent peak at 27.85 minutes which 
was initially assigned as an unknown compound X with m/z 499.2310 for its [M+H]+ 
precursor ion as shown in Fig. 3 (A). The suspected-target screening revealed 
matching for two possible structural isomers, namely 3,5-dimethylpiperazinyl-
dithiodesmethylcarbodenafil [24] and dithiopropylcarbodenafil [25] with a mass error 
of 0.40 ppm for their [M+H]+ precursor ion. Further investigation of the collision-
induced-dissociation (CID) process of compound X revealed two unique fragment ions 
at m/z 371.0995 and m/z 343.0682 which were also present in the CID spectrum of 
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dithiodesmethylcarbodenafil (20) run at 10, 20, and 40 eV CEs, shown in Fig. 3 (B) as 
a representative at 20 eV CE. The data suggest strongly that compound X is a 
structural analogue of dithiodesmethylcarbodenafil with an extra 28 Da mass unit 
(C2H4). Only 2 isomers are shown in Fig. 3 (C) with varying R groups, although many 
other possible R group variations may exist for the structure.  
 
Although the ultimate identity of compound X cannot be concluded with the obtained 
data, the presence of either 3,5-dimethylpiperazinyl-dithiodesmethylcarbodenafil, 
dithiopropylcarbodenafil, or any other possible structural isomers as an adulterant in 
an ICP has not been reported in the literature before. To unambiguously confirm the 
structure of compound X, the use of complementary techniques, such as nuclear 
magnetic resonance (NMR), would be highly valuable following analyte isolation and 
purification. Alternatively, identification might be achieved if the certified reference 
materials of various structural isomers are available. Future investigation for full 
structural elucidation is warranted as compound X might be a novel PDE5 inhibitor.  
 
4. Conclusions 
A modified QuEChERS extraction procedure coupled to LC-HRMS analysis was fully 
optimised and validated to determine PDE5 inhibitors and their analogues found as 
adulterants in ICPs. The process of screening, identification, and quantification were 
done simultaneously with detailed procedures and examples discussed in this study. 
These adulterants were comprehensively screened via the suspected-target and non-
targeted approaches, utilising the full spectral information of the simultaneous MS and 
MS/MS experiments. The optimisation of chromatography, sample extraction, and 
sample dilution led to the minimisation of ME for all 23 targeted PDE5 inhibitors [19]. 
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The applicability of the developed method was then demonstrated using 25 ICP 
samples. Typically, consumers tend to take extra precaution when taking health 
supplements, especially in pharmaceutical dosage form compared to consumable 
products, such as ICPs.  Therefore, this kind of adulterated products will put the public 
at the absolute risk owing to its easy accessibility, either through conventional or online 
markets. The strategies proposed in this study would be beneficial to tackle the 
problems of adulterated ICPs, especially with PDE5 inhibitors and their analogues to 
safeguard the public health. 
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Spectral library (20) 











(average dose per sachet in mg - quantification level) 
Analyte 1 Analyte 2 Analyte 3 Analyte 4 Total analyte 
SPL001 20.21 
Desmethylcarbodenafil  
(106.02 - SPR) 





(2.77 - SUB) 





(0.85 - TRC) 
Propoxyphenyl-thiodimethylsildenafil  
(4.12 - SUB) 
Thiodimethylsildenafil  






(27.03 - SPR) 
Sildenafil  




SPL005 25.50 Compound X* ND ND ND NA 
SPL006 24.40 Hydroxythiohomosildenafil* ND ND ND NA 
SPL007 20.88 
Sildenafil  
(84.93 - THE) 
ND ND ND 
84.93 
THE 
SPL008 20.31 ND ND ND ND ND 
SPL009 25.50 ND ND ND ND ND 
SPL010 30.06 ND ND ND ND ND 
SPL011 8.26 ND ND ND ND ND 
SPL012 21.61 
Sildenafil  
(83.69 - THE) 





(86.56 - THE) 





SPL014 29.67 ND ND ND ND ND 
SPL015 19.23 
Dimethylsildenafil  
(0.60 - TRC) 
Sildenafil  
(0.85 - TRC) 
Thiodimethylsildenafil  
(29.15 - THE) 
Thiosildenafil  
(91.04 - THE) 
121.64 
SPR 
SPL016 17.59 ND ND ND ND ND 
SPL017 19.66 
Desmethylcarbodenafil  
(9.47 - SUB) 
ND ND ND 
9.47 
SUB 
SPL018 24.13 ND ND ND ND ND 
SPL019 19.18 
Dimethylsildenafil  
(1.32 - TRC) 
Thiosildenafil  
(22.18 - SUB) 
Thiodimethylsildenafil  








(2.33 - SUB) 
Sildenafil  






(36.02 - SPR) 





(68.90 - THE) 
ND ND ND 
68.90 
THE 





(1.11 - TRC) 
Thiodimethylsildenafil  
(31.40 - THE) 
Thiosildenafil  





(3.08 - SUB) 
Sildenafil  
(4.43 - SUB) 
Thiodimethylsildenafil  
(8.59 - SUB) 
Thiosildenafil  
(40.50 - THE) 
56.60 
THE 
Notes: ND: not detected, TRC: trace, SUB: subtherapeutic, THE: therapeutic, SPR: supratherapeutic, NA: not applicable *suspected-target 
screening 
